Phillip Md Et Al Frost Purchases 25,000 Shares of Cocrystal Pharma (NASDAQ:COCP) Stock

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost purchased 25,000 shares of Cocrystal Pharma stock in a transaction that occurred on Wednesday, December 24th. The stock was acquired at an average cost of $0.97 per share, with a total value of $24,250.00. Following the transaction, the director owned 1,728,551 shares in the company, valued at $1,676,694.47. This trade represents a 1.47% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, December 26th, Phillip Md Et Al Frost acquired 40,000 shares of Cocrystal Pharma stock. The shares were acquired at an average price of $0.97 per share, for a total transaction of $38,800.00.
• On Wednesday, November 26th, Phillip Md Et Al Frost acquired 4,000 shares of Cocrystal Pharma stock. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $3,960.00.
• On Tuesday, November 25th, Phillip Md Et Al Frost bought 20,000 shares of Cocrystal Pharma stock. The shares were acquired at an average cost of $0.94 per share, with a total value of $18,800.00.

Cocrystal Pharma Trading Up 2.5%

Shares of COCP traded up $0.02 on Monday, reaching $1.00. The company’s stock had a trading volume of 62,528 shares, compared to its average volume of 426,375. The firm has a fifty day moving average of $1.03 and a 200-day moving average of $1.33. The stock has a market capitalization of $13.74 million, a PE ratio of -1.06 and a beta of 1.04. Cocrystal Pharma, Inc. has a twelve month low of $0.90 and a twelve month high of $3.26.

Cocrystal Pharma (NASDAQ:COCP) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.03. As a group, equities analysts anticipate that Cocrystal Pharma, Inc. will post -1.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.